[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transfusion-dependent-non-severe-aplastic-anemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transfusion-dependent-non-severe-aplastic-anemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100635880","phase-2-csaepaghpagromiplostim-n01-in-newly-diagnosed-saatd-nsaa-100635880",false,"NCT07558434","CsA+EPAG\u002FHPAG+Romiplostim N01 in Newly-diagnosed SAA\u002FTD-NSAA","Cyclosporine + Eltrombopag\u002FHetrombopag + Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia\u002F Severe Aplastic Anemia","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Diagnosed with aplastic anemia (AA) through routine blood tests, bone marrow puncture, bone marrow biopsy, and exclusion tests, and determined as transfusion-dependent non-severe aplastic anemia (TD-NSAA) or severe aplastic anemia (SAA) according to the Camitta criteria; Platelet \\\u003C 30×10\\^9\u002FL;\n3. Had no HLA-matched donors or was not suitable for first-line allogeneic hematopoietic stem cell transplantation (HSCT);\n4. Not suitable for ATG, due to reasons such as age, complications, and the patient's own wishes;\n5. With baseline liver and kidney functions \\\u003C2 ULN;\n6. ECOG score ≤ 2;\n7. Signed the informed consent;\n\nExclusion Criteria:\n\n1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;\n2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;\n3. PNH clone ≥ 50%;\n4. Received HSCT before enrollment;\n5. Previously used immunosuppressive treatments such as ATG, CsA, TPO receptor agonists (TPO-RAs);\n6. Allergic or intolerant to romiplostim N01, eltrombopag, hetrombopag, or CsA;\n7. Pregnant or lactating patients;\n8. Severe bleeding or infection that cannot be controlled by standard treatment;\n9. History of arterial or venous thrombosis;\n10. Complicated with malignant tumors;\n11. Participated in other clinical trials within 3 months;\n12. Patients considered not suitable to participate in this study by the investigator.","ALL","18 Years",{"count":19,"type":20},43,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study aimed to explore the efficacy and safety of cyclosporine (CsA)\n\n+eltrombopag (EPAG)\u002Fhetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)",[26,27],"Severe Aplastic Anemia (SAA)","Transfusion-dependent Non-severe Aplastic Anemia","NOT_YET_RECRUITING","2026-04-23",{"date":31,"type":32},"2026-04-30","ACTUAL",{"date":34,"type":20},"2026-04",{"date":36,"type":20},"2029-12",{"name":38,"class":39},"Peking Union Medical College Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":57,"locationsCount":4},"100635129","phase-3-enarodustat--csa-vs-csa-in-newly-diagnosed-td-nsaa-100635129","NCT07548671","Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA","Efficacy and Safety of Enarodustat Combined With Cyclosporine Versus Cyclosporine Monotherapy in the Treatment of Newly Diagnosed TD-NSAA","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Diagnosed with aplastic anemia (AA) through routine blood tests, bone marrow puncture, bone marrow biopsy, and exclusion tests, and determined as transfusion-dependent non-severe aplastic anemia (TD NSAA) according to the Camitta criteria; Hemoglobin\\\u003C90g\u002FL;\n3. Had no HLA-matched donors or was not suitable for first-line allogeneic hematopoietic stem cell transplantation (HSCT);\n4. With baseline liver and kidney functions \\\u003C2 ULN;\n5. ECOG score ≤ 2;\n6. Signed the informed consent;\n\nExclusion Criteria:\n\n1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;\n2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;\n3. PNH clone ≥ 50%;\n4. Received HSCT before enrollment;\n5. Previously used immunosuppressive treatments such as ATG, CsA, TPO receptor agonists (TPO-RAs), roxadustat;\n6. Allergic or intolerant to enarodustat or CsA;\n7. Pregnant or lactating patients;\n8. Severe bleeding or infection that cannot be controlled by standard treatment;\n9. Complicated with malignant tumors;\n10. Participated in other clinical trials within 3 months;\n11. Patients considered not suitable to participate in this study by the investigator.",{"count":48,"type":20},90,[50],"PHASE3","This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).",[27],"2026-04-16",{"date":29,"type":32},{"date":34,"type":20},{"date":36,"type":20},{"name":38,"class":39},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100590250","treatment-of-transfusion-dependent-nonsevere-aplastic-anemia-with-luspatercept-a-multicenter-prospective-clinical-study-100590250","NCT06964971","Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* 1.Age \\>= 18 years; 2.According to the \"Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition)\", the patient must be diagnosed with transfusion-dependent non-severe aplastic anemia (TD-NSAA) and meet the requirement of erythroid hyperplasia in bone marrow aspiration from the posterior iliac crest and\u002For sternum being more than 15%; 3.If not newly diagnosed with TD-NSAA, and there are combined primary disease maintenance medications, the following conditions must be met:\n\n  1. The patient has not received and does not consider HSCT or ATG treatment for at least the next six months;\n  2. If maintaining oral immunosuppressive therapy, the course must be at least 6 months and assessed as ineffective;\n  3. If maintaining androgen therapy, the course must be at least 3 months and assessed as ineffective;\n  4. If maintaining recombinant human erythropoietin therapy, the course must be at least 3 months and assessed as ineffective;\n  5. If maintaining thrombopoietin receptor agonist (TPO-RA) therapy, the duration must be \\>=6 months with confirmed inefficacy, and a washout period of \\>=1 month is required before study enrollment;\n  6. If the above maintenance medication durations are not met, a washout period of at least 1 month is required; 4.Serum ferritin level \\>= 1000 ng\u002Fml; 5.Complete whole exome sequencing and MDS\u002FAA next-generation sequencing testing are required.\n\nExclusion Criteria:\n\n* 1\\. Severe hepatic dysfunction (ALT or AST ≥ 3 × ULN); 2.Severe renal impairment (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or patients with end-stage renal disease); 3.Cardiac disease, including New York Heart Association (NYHA) Class 3 or higher heart failure, or severe arrhythmia requiring treatment, or recent myocardial infarction within 6 months of randomization; 4.Patients with uncontrolled hypertension, with controlled hypertension according to NCI CTCAE version 5.0 considered as ≤ Grade 1 for this protocol; 5.Patients with a PNH clone \\> 1%; 6.Patients planning to become pregnant or who are pregnant; 7.Surgical or clinical conditions that may significantly alter drug absorption, distribution, metabolism, or excretion (e.g., gastritis, ulcers, history of gastrointestinal or rectal bleeding; history of major gastrointestinal surgery); 8.Patients carrying congenital bone marrow failure-related gene mutations (homozygous or heterozygous, regardless of whether they are pathogenic\u002Fbenign\u002Flikely benign\u002F of uncertain significance).","80 Years",{"count":48,"type":20},[67],"NA","The goal of this clinical trial is to learn whether Luspatercept alone or in combination with Deferasirox can promote hematopoietic function in patients with transfusion-dependent non-severe aplastic anemia, as well as to assess the safety and efficacy of this treatment approach.\n\nThe main questions it aims to answer is:\n\nwhether the combination therapy of Luspatercept and Deferasirox can improve hemoglobin levels in these patients.\n\nParticipants will receive Luspatercept every 3 to 5 weeks based on hemoglobin response, undergo complete blood counts every 1 to 3 weeks, and receive other necessary evaluations as required.",[27],"2025-05-07",{"date":72,"type":32},"2025-05-11",{"date":74,"type":20},"2025-05-20",{"date":76,"type":20},"2027-06-30",{"name":78,"class":39},"The First Affiliated Hospital of Zhejiang Chinese Medical University",1]